EUVIMEDEUVIMED entdecken
Kontrollierte klinische Studie

Impact of cardiopulmonary bypass on cefuroxime plasma and interstitial tissue concentrations in patients undergoing cardiac bypass surgery—a prospective controlled clinical trial

Stefanie Nothofer iD, Christian Dumps, Christoph Dorn, Constantin Lier, Manfred Weiss, Markus Zeitlinger, Sina Stock, Evaldas Girdauskas iD, Axel Ruediger Heller, Philipp Simon

Journal of Antimicrobial Chemotherapy · 05.05.2026 · 81 (6)

DOI: 10.1093/jac/dkag171 ↗

Kurz gefasst

Kontrollierte klinische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 19.05.2026. Verfasst von Stefanie Nothofer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Anaesthesiology and Operative Intensive Care, Faculty of Medicine, University of Augsburg, Augsburg, Germany. Hauptthemen laut MEDLINE: Cefuroxime, Cardiopulmonary Bypass, Anti-Bacterial Agents, Plasma. Die Arbeit nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Cardiopulmonary bypass (CPB) alters the pharmacokinetics (PK) of antibiotics administered as surgical prophylaxis (SAP) due to haemodilution, circuit interactions, protein binding and inflammation. This study investigated plasma and interstitial fluid (ISF) concentrations of cefuroxime in patients undergoing on- versus off-pump coronary artery bypass graft (CABG) surgery.

Methods

Patients undergoing on- or off-pump CABG received SAP with cefuroxime, consisting of a bolus of 3 g before skin incision and a second dose of 1.5 g at CPB weaning or at sternal closure, respectively. ISF concentrations were measured by two microdialysis catheters in the subcutaneous tissue of both upper arms. Plasma and ISF concentrations were determined up to 8 hours after the first dose. Pharmacokinetic analysis was performed by non-compartmental analysis.

Results

Fifteen patients were enrolled per group. Baseline characteristics and cardiovascular risk profile were comparable between groups. Median [minimum; maximum] surgical duration was 4.3 h [3.1 h; 6.1 h] in the on-pump and 3.4 h [1.8 h; 4.0 h] in the off-pump group, with a median bypass time of 1.7 h [0.8 h; 2.5 h]. The ƒAUC0−8h in plasma (on-pump versus off-pump group; mean ± SD: 417 ± 124 versus 542 ± 238 h·mg/L, P = 0.081) and in ISF (488 ± 212 versus 508 ± 209 h·mg/L, P = 0.835) did not differ significantly. Based on an extrapolation of the first dose, plasma concentrations remained above a minimum inhibitory concentration of 8 mg/L for up to 4.5 h in the on-pump and 4.8 h in the off-pump group.

Conclusion

For a median bypass time of 1.7 h and considering all factors cumulatively, no significant impact of CPB on cefuroxime plasma and ISF concentrations was observed. A dose of 3 g cefuroxime administered intravenously 30–60 min before skin incision with a second repetitive dose of 1.5 g administered after CPB weaning in the on-pump group or after sternal closure in the off-pump group, resulted in adequate plasma and ISF concentrations in patients undergoing cardiac bypass surgery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CefuroximeCardiopulmonary BypassAnti-Bacterial AgentsPlasmaExtracellular FluidAntibiotic ProphylaxisCoronary Artery BypassHumansFemaleMaleAgedProspective StudiesMiddle Aged

Substanzen

CefuroximeAnti-Bacterial Agents

Autor:innen und Institutionen

  • Anaesthesiology and Operative Intensive Care, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
  • Institute of Pharmacy, University of Regensburg, Regensburg, Germany.
  • Department of Clinical Pharmacology, Medical University Vienna, Vienna, Austria.
  • Cardiothoracic Surgery, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
  • Department of Cardiovascular Surgery, Faculty of Medicine, University Hospital Hamburg-Eppendorf, Hamburg, Germany.

ORCID-Profile: Stefanie Nothofer, Evaldas Girdauskas

Zitieren

APA

Nothofer, S., Dumps, C., Dorn, C., Lier, C., Weiss, M., Zeitlinger, M., Stock, S., Girdauskas, E., Heller, A. R., & Simon, P. (2026). Impact of cardiopulmonary bypass on cefuroxime plasma and interstitial tissue concentrations in patients undergoing cardiac bypass surgery—a prospective controlled clinical trial. Journal of Antimicrobial Chemotherapy, 81(6). https://doi.org/10.1093/jac/dkag171

Vancouver

Nothofer S, Dumps C, Dorn C, Lier C, Weiss M, Zeitlinger M, et al. Impact of cardiopulmonary bypass on cefuroxime plasma and interstitial tissue concentrations in patients undergoing cardiac bypass surgery—a prospective controlled clinical trial. Journal of Antimicrobial Chemotherapy. 2026;81(6). doi:10.1093/jac/dkag171

BibTeX
@article{Nothofer2026,
  author = {Nothofer, Stefanie and Dumps, Christian and Dorn, Christoph and Lier, Constantin and Weiss, Manfred and Zeitlinger, Markus and Stock, Sina and Girdauskas, Evaldas and Heller, Axel Ruediger and Simon, Philipp},
  title = {Impact of cardiopulmonary bypass on cefuroxime plasma and interstitial tissue concentrations in patients undergoing cardiac bypass surgery—a prospective controlled clinical trial},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  volume = {81},
  number = {6},
  doi = {10.1093/jac/dkag171}
}
Kostenlos starten →